KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Average (2016 - 2025)

Historic Equity Average for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to $30.4 million.

  • Nektar Therapeutics' Equity Average fell 5265.3% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 5265.3%. This contributed to the annual value of $95.9 million for FY2024, which is 6147.22% down from last year.
  • Per Nektar Therapeutics' latest filing, its Equity Average stood at $30.4 million for Q3 2025, which was down 5265.3% from -$5.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Equity Average high stood at $1.0 billion for Q1 2021, and its period low was -$5.2 million during Q2 2025.
  • For the 5-year period, Nektar Therapeutics' Equity Average averaged around $360.0 million, with its median value being $218.9 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 2331.82% in 2021, then crashed by 10507.43% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Equity Average stood at $740.5 million in 2021, then tumbled by 47.41% to $389.4 million in 2022, then tumbled by 62.72% to $145.2 million in 2023, then crashed by 62.25% to $54.8 million in 2024, then plummeted by 44.47% to $30.4 million in 2025.
  • Its Equity Average stands at $30.4 million for Q3 2025, versus -$5.2 million for Q2 2025 and $37.2 million for Q1 2025.